In short
Clinical trials of Rotigotine are studying how well it works and how safe it is in different patient groups. The trials include people with Parkinson’s disease, mild to moderate Alzheimer’s disease, and autosomal dominant polycystic kidney disease. They also measure patch adhesion, cognitive outcomes, and safety over time.
Key points
- Clinical trials of Rotigotine are being done in different diseases, not just one condition. One completed Phase 2 study in Parkinson’s disease looked at how well a patch sticks to the skin. A Phase 3 study in mild to moderate Alzheimer’s disease is testing whether Rotigotine with rivastigmine improves frontal lobe thinking skills better than rivastigmine with placebo. Another Phase 2 study in autosomal dominant polycystic kidney disease is focused on safety over 24 months. The studies include small and large groups, and they measure outcomes such as adhesion, cognitive change, and adverse reactions.
Clinical trials overview
These studies of Rotigotine are testing different research questions in different patient groups. One study is in people with Parkinson’s disease, one is in people with mild to moderate Alzheimer’s disease, and one is in people with autosomal dominant polycystic kidney disease (ADPKD).
The trial designs are interventional, which means the researchers give a study treatment and then measure the results. The studies include Phase 2 and Phase 3 trials, so they range from earlier testing to larger confirmatory research.
Parkinson’s disease patch-adhesion study
This completed Phase 2 trial studied whether a new Rotigotine patch stayed attached to the skin in people with Parkinson’s disease. The study enrolled 24 participants and compared the test patch with a reference patch product.
The main endpoint was adhesion, which means how well the patch sticks to the skin during the dosing period. The trial measured the mean adhesion of the test patch at 23 hours and 55 minutes, which is almost the end of the wearing time. It also measured the difference in adhesion between the test and reference products at that same time point.
This study was focused on a practical question: whether the patch remains in place for the full dosing interval in real use.
Alzheimer’s disease Phase 3 study
This Phase 3 study is a prospective, randomized, double-blind, placebo-controlled, parallel-group, international, multi-center trial in mild to moderate Alzheimer’s disease. It enrolled 378 participants.
The study is evaluating Rotigotine in combination with rivastigmine and comparing it with rivastigmine plus placebo. In simple terms, the trial is asking whether adding Rotigotine to the background treatment gives better results than not adding it.
The main endpoint is the change from baseline to Week 24 in the FAB, which stands for Frontal Assessment Battery. This is a test of frontal lobe cognitive function, meaning thinking skills such as planning, attention, and decision-making.
The trial uses a placebo, which is an inactive patch that looks like the active one, so the comparison stays fair. The study is authorised, meaning it has approval to proceed.
Kidney disease safety study
This Phase 2 study, called ETERNAL-PKD, is looking at the safety of Rotigotine in patients with autosomal dominant polycystic kidney disease. It is authorised and plans to enroll 120 participants.
The study is evaluating Rotigotine given at 4 mg/24 hours for 24 months, with safety as the main focus. The brief summary says the trial is designed to assess safety in ADPKD over this long follow-up period.
The main safety endpoint is the occurrence of adverse reactions and serious adverse reactions during 24 months of follow-up. The study especially looks at the proportion of participants who have at least one serious adverse reaction, including serious reactions at the application site or certain behavioral disorders.
Main endpoints and what they mean
Clinical trials use endpoints to decide what result matters most. In these studies, the endpoints are very different because each trial has a different goal.
- In Parkinson’s disease, the endpoint is patch adhesion, so the researchers are checking whether the patch stays on the skin as planned.
- In Alzheimer’s disease, the endpoint is change in FAB score from baseline to Week 24, so the researchers are checking whether thinking skills related to the frontal lobe change over time.
- In ADPKD, the endpoint is safety over 24 months, especially the number of participants with adverse reactions or serious adverse reactions.
Who the trials are for
The Parkinson’s disease study is for people with Parkinson’s disease, and it focuses on patch performance rather than symptoms alone.
The Alzheimer’s disease study is for people with mild to moderate Alzheimer’s disease and tests whether Rotigotine can add benefit when used with rivastigmine.
The kidney study is for people with ADPKD, a type of kidney disease with many cysts, and it mainly looks at long-term safety.
Together, these trials show that Rotigotine is being studied across different patient groups, with outcomes that match each disease and research question.